<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875886</url>
  </required_header>
  <id_info>
    <org_study_id>NL54748.078.15</org_study_id>
    <nct_id>NCT02875886</nct_id>
  </id_info>
  <brief_title>DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease</brief_title>
  <acronym>DD</acronym>
  <official_title>DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      In this clinical study the anti-hypertensive response to dietary salt restriction is compared
      with the anti-hypertensive response to the diuretics hydrochlorothiazide/amiloride in adult
      patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic kidney disease (CKD) are exquisitely salt-sensitive. Salt-sensitivity
      in CKD is linked to hypertension and cardiovascular outcomes. Dietary salt restriction is an
      accepted intervention for salt-sensitivity in CKD. Another strategy, however, could be to
      block sodium uptake by the kidney pharmacologically by diuretics. Especially diuretics acting
      on the distal tubule may be effective, because this appears to be the site of increased
      sodium reabsorption in CKD. It is currently unknown how these two strategies, diet or
      diuretics, relate. The investigators hypothesize that diuretics are non-inferior to diet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour blood pressure</measure>
    <time_frame>Two weeks after start of each intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Diuretic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive amiloride and hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-sodium diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are put on a low-sodium diet (60 mmol/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Combined with hydrochlorothiazide</description>
    <arm_group_label>Diuretic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Combined with amiloride</description>
    <arm_group_label>Diuretic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-sodium diet</intervention_name>
    <arm_group_label>Low-sodium diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  CKD stage 3 or 4 (MDRD-GFR 15-60 ml/min)

          -  Use of any anti-hypertensive drugs

          -  No anti-hypertensive drugs but an average office systolic blood pressure &gt; 140 mmHg
             (as measured by datascope)

        Exclusion Criteria:

          -  Salt-wasting CKD

          -  Nephrotic syndrome

          -  Pregnant or breastfeeding women

          -  Life expectancy &lt; 6 months

          -  Severe heart failure (NYHA III or IV) or liver cirrhosis with ascites and the
             inability to withdraw diuretics

          -  Rapidly declining kidney function with high likelihood of dialysis or kidney
             transplantation in the coming 4 months

          -  Kidney transplant recipients

          -  Use of immunosuppressive drugs

          -  Use of non-steroidal anti-inflammatory drugs

          -  Previous intolerance or allergy to hydrochlorothiazide or amiloride

          -  Serum sodium &lt; 135 mmol/l

          -  Serum potassium &lt; 3.5 mmol/l or &gt; 5.0 mmol/l

          -  Inability to adhere to the study protocol (due to language, incapacitated subjects,
             subjects with intellectual disability)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meng L, Fu B, Zhang T, Han Z, Yang M. Salt sensitivity of blood pressure in non-dialysis patients with chronic kidney disease. Ren Fail. 2014 Apr;36(3):345-50. doi: 10.3109/0886022X.2013.866008. Epub 2013 Dec 17.</citation>
    <PMID>24345270</PMID>
  </reference>
  <reference>
    <citation>McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015 Feb 18;(2):CD010070. doi: 10.1002/14651858.CD010070.pub2. Review.</citation>
    <PMID>25691262</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171-82. doi: 10.1159/000358603. Epub 2014 Feb 11.</citation>
    <PMID>24526255</PMID>
  </reference>
  <reference>
    <citation>Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin J Am Soc Nephrol. 2011 Aug;6(8):1845-50. doi: 10.2215/CJN.08190910. Epub 2011 Jul 22.</citation>
    <PMID>21784839</PMID>
  </reference>
  <reference>
    <citation>Levy Yeyati N, Fellet A, Arranz C, Balaszczuk AM, Adrogu√© HJ. Amiloride-sensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease. J Nephrol. 2008 Jan-Feb;21(1):93-8.</citation>
    <PMID>18264941</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Internist nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

